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Background: For many years, placebo has been defined by its inert content and use in clinical 
trials. In recent years, several studies have demonstrated its effect in the treatment of major 
depression. The aim of this paper is to present the conclusions of recent meta-analyses of the 
placebo effect in major depression, to explain the mechanism by which placebo exerts its effect, 
and to discuss whether placebo can be used in the treatment of patients with major depression in 
clinical practice. Recent meta-analyses have demonstrated that the placebo effect is estimated to 
account for 67% of the treatment effect in patients receiving antidepressants, and furthermore 
that placebo is as effective as antidepressants in patients with mild to moderate major depression 
(reporting a Hamilton Depression Rating Scale score lower than 25), whereas placebo is less 
effective than antidepressants in severely depressed patients. However, several limitations make 
the translation of these conclusions into clinical practice impracticable. Clinicians should learn 
from the “placebo lesson” to maximize the nonspecific effects of treatment when they prescribe 
an antidepressant, particularly in less severely depressed patients, who show a higher placebo 
response in randomized controlled trials. This strategy can increase the antidepressant effect 
and may reduce nonadherence with treatment.
Keywords: placebo effect, major depressive disorder, subthreshold depressive disorder, 
antidepressants
Introduction
In recent years, the placebo effect had received increasing attention in the treatment 
of depressive disorders, given that data from randomized controlled trials (RCTs) 
suggest that the placebo effect is estimated to account for 67% of the treatment effect 
in patients receiving antidepressants.1
Data from other recent RCTs confirm the clinical meaningful effect of placebo in 
depressed patients, and have opened up a debate as to the usefulness of antidepressants. 
The present paper summarizes the recent data on the placebo effect in the treatment 
of major depression with the aim of evaluating whether placebo can also be used 
successfully in clinical practice.
Materials and methods
We search the MEDLINE/PubMed database for papers published in the English 
language between January 2007 and December 2012, using the terms “placebo OR 
placebo effect” AND “depression”, AND “antidepressant”. The search was limited to 
meta-analyses and reviews, and those judged not to be pertinent or less relevant were 
excluded. Reference lists of reviews and meta-analyses were also hand-searched for 
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further relevant reports. Using this strategy, we identified 
23 papers.
Discussion
Placebo effect in major depression
The placebo effect in the treatment of patients with major 
depression is supported by many placebo-controlled trials, 
in which the rate of patients with depression showing 
an improvement in symptoms was estimated to be about 
30%.2 In recent years, the magnitude of the placebo effect 
has been suggested to be clinically relevant, particularly in 
mildly to moderately depressed patients. A meta-analysis 
of 35 short-term RCTs submitted to the US Food and Drug 
Administration for regulatory approval (also including 
unpublished studies) found little evidence for the efficacy 
of antidepressants in patients whose depression was not 
severe, unless alternative treatments had failed to provide 
benefit.3 This finding was confirmed in a recent meta-
analysis of six RCTs, which demonstrated that the efficacy 
of antidepressants, compared with placebo, increases with 
the severity of depressive symptoms, being minimal or null 
in patients with mild or moderate depression and substantial 
in patients with severe depression.4 The authors found that 
antidepressants were superior to placebo only in patients 
with a pre-treatment Hamilton Depression Rating Scale 
(HDRS) score higher than 24.5 This result was recently 
confirmed by Leucht et al who analyzed the efficacy of 
amitriptyline compared with placebo in the treatment of 
major depressive disorder.6
However, the results of these studies were not unanimou sly 
accepted. The conclusion of Kirsch et al was criticized by 
Mathew and Charney chiefly for the use, as a measure 
of outcome, of the mean difference in HDRS between 
antidepressants and placebo at the end of the studies, 
rather than the more clinically meaningful response or 
remission rate, and for the potentially severe consequences 
of undertreating depressed patients using placebo (risk 
of suicide, disability, and familial, vocational, or social 
dysfunction).3,7 A recent meta-analysis on the outcome of 
placebo versus antidepressants in RCTs concluded that 
drug-placebo differences may be improved by inclusion of 
fewer sites and subjects, and use of better quality control in 
diagnostic and clinical assessments.8
Moreover, the data from the above-mentioned meta-
analyses are contradicted by the results of a review of 
14 short-term RCTs conducted in the primary care setting, 
in which less severely depressed patients are usually treated. 
The review found a higher response/remission rate in patients 
treated with selective serotonin reuptake inhibitors or tricyclic 
antidepressants than in patients receiving placebo.9
Collected together, these data open a scientific and 
clinical debate concerning the treatment of mild to moderate 
forms of major depression, because: these accounted for 
49% of all episodes of major depression;10 mild severity 
(HDRS scores less than 22) was found in 71% of depressed 
outpatients seeking treatment;11 and participation in RCTs of 
patients with milder, briefer, and more responsive forms of 
depression could have contributed to the two-fold increase 
in the placebo response observed in clinical trials conducted 
from 1980 to 2005.1,12
The aforementioned RCT data, even where contradictory 
and open to criticism, suggest that placebo seems to be 
as effective as antidepressants in the treatment of patients 
with mild to moderate depression, whereas placebo is less 
effective than antidepressants in the treatment of patients 
with severe depression. However, they leave unresolved 
the question of whether and how the patient with mild to 
moderate depression might be successfully treated with 
placebo in clinical practice.
Placebo effect in subthreshold depression
The advent of operational criteria in the Diagnostic and 
Statistical Manual of Mental Disorders, Third Edition and 
its subsequent editions for the diagnosis of major depression 
has brought patients with subthreshold major depression to 
clinical attention. Even though this approach was criticized 
for the risk of treating normal emotional states as illness 
and challenging the model’s credibility, subthreshold major 
depression had received increasing attention, particularly in 
depressed patients with medical illness (eg, cardiovascular 
disease), for the recognized negative effect of depression on 
the outcome of medical conditions.13–20 Moreover, subthreshold 
major depression can represent the residual symptoms of 
major depression, increasing the risk of recurrence, which 
needs to be adequately prevented. Therefore, in the conditions 
mentioned above, the treatment of subthreshold major 
depression has become a matter of clinical interest. Placebo is 
expected to exert a meaningful clinical effect in the treatment 
of such depressed patients, according to the point of view that 
the mild forms of major depression are responsive to placebo. 
A recent meta-analysis confirmed that there is no evidence of 
superiority for antidepressants compared with placebo in the 
treatment of patients with subthreshold major depression.21 
However, use of placebo in the treatment of subthreshold 
depression should be considered with caution in patients with 
severe medical illness and in patients with a history of severe 
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major depression, because placebo would be ineffective in 
these patients (see below).
How does placebo exert  
an antidepressant effect?
The placebo effect should not be confused with other causes 
of healing, such as spontaneous improvement, the Hawthorne 
effect (ie, the subject improves simply in response to the fact 
that she/he is being studied and not in response to any par-
ticular experimental manipulation), regression to the mean, 
patient or doctor evaluation bias, and possibly unidentified 
effects of cointervention.22,23 The placebo effect can be 
defined as a biologic or psychologic response induced by 
administration of pills, liquids, or injections of substances 
without a specific effect in relation to the disease needing 
treatment.24,25
One of the more considered explanations of the placebo 
effect is the “expectation theory”, which considers the 
placebo effect to be the result of the subject’s expectation 
that a treatment will be effective for her/his illness.26 This 
expectation is based on personal beliefs, previous experi-
ences, conditioning, the context of treatment, and a positive 
relationship with the doctor.27–31 Hence a better definition of 
placebo would be the one proposed by Brody, ie, “a change 
in patient’s illness attributable to the symbolic import of a 
treatment rather than a specific pharmacological or physi-
ological property”.32
The role of expectation in the placebo response is also 
demonstrated in RCTs. In a recent review of 90 clinical 
trials, which included patients with nonpsychotic unipolar 
depression, the placebo response was influenced by the 
probability of receiving an active treatment, and the placebo 
response rates were higher in RCTs using a three-arm design, 
with two groups receiving antidepressants and one group 
receiving placebo, than in RCTs using a two-arm design (one 
receiving antidepressants and one receiving placebo).33 The 
opposite was observed for antidepressants, in that response 
rates to antidepressants were lower in studies including a 
placebo arm. Also, in a previous report, response rates to 
antidepressants were lower in placebo-controlled trials (46%) 
than in trials comparing the effect of two antidepressants 
(60%).34 These studies suggest that the patient’s expectation 
of receiving an antidepressant increases the placebo response, 
whereas the expectation to receive placebo decreases the 
response to an antidepressant.
Further, the investigator’s expectations can be involved 
in the placebo effect, in that the increased placebo response 
observed from 1980 and 2005 in RCTs was found only in 
trials using rating scales completed by an observer and not 
in those using self-reported rating scales, suggesting that 
investigators tended to overestimate positive changes in 
patients, perhaps because enthusiasm about the efficacy 
of a new antidepressant can induce high expectations for 
improvement.1
Interestingly, expectation of improvement can play 
a role in treatment regardless of the type of treatment 
administered, as suggested by Miller and Colloca, who found 
that expectation-induced therapeutic effects could enhance 
the patient response to placebo and to pharmacologic and 
nonpharmacologic treatments.35 Alleviation of demoralization 
might be a possible explanation for this effect, ie, if the patient 
accepts that her/his stressful condition is overwhelming 
their abilities to cope (demoralization) and decides to seek 
help, their demoralization improves and the condition 
ameliorates.36 This mechanism might also be involved in the 
treatment of depressed patients, who are often demoralized. 
Demoralization can be viewed as a step in a sequence, 
starting with loss of interest and pleasure, and if the loss of 
pleasure and interest becomes pervasive, demoralization 
can follow.37,38 Therefore, any kind of treatment (placebo, 
antidepressants, psychotherapy) alleviating demoralization 
can improve a depressive disorder to some extent.
Although there is a lack of data on the neurobiology of 
the placebo effect in depression, some authors have reported 
that placebo induces release of dopamine in the ventral 
striatum in patients with Parkinson’s disease.39 Interestingly, 
the amount of dopamine release was associated with the 
level of expectation.40 It cannot be excluded that this effect 
could be also active when a placebo induces improvement 
in depressive symptoms, since a reward deficit mediated by 
dysfunction of the dopaminergic pathways is believed to be 
present in major depression.41–43
Is placebo useful in clinical practice?
Care provided in the clinical practice setting is significantly 
different from that in RCTs, so conclusions about the placebo 
effect derived from RCTs cannot be automatically transferred 
to treatment provided in clinical practice.
In clinical practice, many factors could reduce the 
placebo effect seen in RCTs, including: severity of illness, 
ie, patients with severe major depression (and suicide risk) 
are excluded from RCTs but need to be treated in clinical 
practice, so the severity of major depression influences 
the choice and setting of treatment; baseline patient 
characteristics, ie, in a naturalistic study, patients eligible 
for an RCT and patients not eligible differ significantly 
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on several baseline measures;44 the context of treatment, 
ie, visits and evaluations are frequent in RCTs, and the 
increasing number of follow-up assessments enhances 
the placebo response, even though this effect is observed 
for antidepressants too,45,46 and more time is dedicated to 
the patient at each visit so motivation is high, whereas 
comparable characteristics cannot be easily obtained 
in clinical practice; the role of patient and clinician 
expectations of a placebo effect, ie, the placebo effect is 
increased in RCTs due to the expectation to receive (patient) 
or to prescribe (doctor) an active treatment, whereas this 
situation is not yet feasible in clinical practice, due to the 
impossibility of prescribing a placebo without deception 
(see below);34 the outcome of treatment, ie, the chance to 
respond to antidepressant treatment is better in patients 
enrolled in a RCT than in patients treated in clinical 
practice, as demonstrated in the STAR*D (Sequenced 
Treatment Alternatives to Relieve Depression) naturalistic 
cohort for patients eligible for a RCT compared with 
patients not eligible, and by a recent review, in which the 
antidepressant efficacy estimates in RCTs were larger than 
those in observational studies.47,48
Among the above-mentioned variables, the condition 
which makes placebo clinically impractical, even in the 
treatment of patients with mild to moderate depression 
(the only patients who respond to placebo in RCTs), is the 
question of how to obtain from the patient an expectation to 
be treated with an active compound. The “watchful waiting” 
procedure is not comparable with administration of placebo, 
given that less expectation is created by this practice because 
no treatment is prescribed, and may even be detrimental to 
the patient.49 The greatest barrier to use of placebo is its 
prescription without deception, since informing patients 
accurately that they are being given a placebo should prevent 
its effect. A possible solution is suggested by Kirsch: “if 
a convincing rationale can be presented, perhaps placebo 
can be prescribed openly without deception.”50 The method 
consists of telling the patients that placebo has been shown 
to be effective for their condition, that its effect is induced 
at least in part by a well-known mechanism (classical 
conditioning), and that for this reason, taking a placebo pill 
could work as a new treatment. This strategy ameliorates 
symptoms in patients with irritable bowel syndrome and its 
effect has been shown to be superior to no treatment and as 
large as that produced by commonly prescribed medication 
for the syndrome.51
Even though this strategy is interesting from a scientific 
point of view, its effect has not yet been evaluated in the 
treatment of patients with mild to moderate depression, 
and therefore it should not be recommended in clinical 
practice. Moreover, clinicians should keep in mind the fol-
lowing issues. All the international guidelines for treatment 
of major depression, even though recognizing the relevance 
of the placebo effect, do not recommend placebo (instead of 
antidepressants or psychotherapy) in the acute treatment 
of nonsevere forms or in the prevention of recurrence,52–55 
and there is evidence that placebo is not as effective as 
antidepressants in mildly depressed patients with medical 
comorbidity.18 For example, in mildly depressed patients 
with myocardial infarction, the risk of cardiac death is 
reduced by use of a selective serotonin reuptake inhibitor, 
such as citalopram, but not by usual care or psychotherapy, 
suggesting that antidepressants have superior efficacy com-
pared with alternative treatments in these patients.56–58 In 
patients with subthreshold depression and a previous history 
of severe major depression (subthreshold depression being 
a risk factor for a new episode), placebo seems not to be as 
effective as antidepressants in the prevention of recurrence, 
and a recent guideline recommends use of antidepressants 
in these patients.55
Finally, from a cost-benefit point of view, the widespread 
use of generic antidepressant formulations reduces the cost of 
antidepressant therapy, and thereby also the attractiveness of 
less costly alternatives (placebo) for health services, which 
may be concerned with better expenditure of resources.
For the reasons outlined above, placebo is not recom-
mended in the treatment of major depression in clinical 
practice, because of patient peculiarities, frequent medical 
comorbidities, and for now, the impossibility of administering 
it without deception.
Conclusion
Even though contradictory and criticized, the RCT data 
suggest that placebo is as effective as antidepressants in the 
acute treatment of patients with mild to moderate depression, 
but is less effective than antidepressants in the treatment 
of severely depressed patients. Even though these findings 
deserve attention due to the possible clinical implications, 
their translation into clinical practice is impracticable for 
the following reasons: patients seeking treatment in daily 
practice are different from those enrolled in RCTs; the inef-
ficacy of treatment, other than antidepressants, in preventing 
the negative effect of mild-moderate depression on medical 
comorbidity (which suggests placebo may be ineffective 
where comorbidity is concerned); and the impossibility of 
administering placebo without deception, even though a 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
918
Marchesi et al
Neuropsychiatric Disease and Treatment 2013:9
strategy to overcome this barrier has been proposed but not 
as yet tested in depressed patients.51
However, clinicians should learn from the “placebo 
lesson” that expectation is a relevant mechanism that 
should be utilized and optimized in clinical practice, given 
that the nonspecific effects of treatment can also act during 
prescription of an active treatment. Therefore, clinicians 
should maximize the nonspecific effects of treatment when 
they prescribe an antidepressant, particularly for less severely 
depressed patients, who show a higher placebo response in 
RCTs. This strategy can increase the antidepressant effect 
and perhaps also reduce nonadherence with treatment, which 
is estimated to be around 40% or even higher, especially 
in outpatients with mild to moderate depression treated in 
clinical practice.49
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